Arcus Biosciences, Inc. (RCUS) Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Arcus Biosciences, Inc. NYSE:RCUS Healthcare · Biotechnology
AH Close $18.54 +0.00% vs close
AH Close $18.54 +0.00% vs close
All Press Release SEC Filings News
SEC Filing ⚠ 2
RCUS: 8-K · offering registration
Arcus Biosciences closed an underwritten follow-on offering on October 23, 2026, selling 16,428,572 shares of common stock at $17.50 per share, including full exercise of the underwriters' 2,142,857-share option.
The underwriters (Jefferies, Leerink Partners, and TD Securities) purchased shares at $16.45, and Arcus received net proceeds of approximately $269.7 million after discounts and expenses.
The offering was made off the company's existing S-3 shelf, and a 60-day lock-up applies to company insiders and the company itself, with limited carve-outs including its Leerink ATM program after a 30-day pause. The capital raise meaningfully extends Arcus's cash runway but dilutes existing shareholders.
SEC 8-K • 2d ago Press Release ⚠ 2
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences priced an underwritten public offering of 14,285,715 shares at $17.50 per share for expected gross proceeds of $250.0 million.
Underwriters hold a 30-day option on up to 2,142,857 additional shares, and the offering is expected to close on October 23, 2026.
Jefferies, Leerink Partners, TD Cowen, Evercore ISI and Mizuho are joint book-running managers; the raise is dilutive for a late clinical-stage biotech, though the article does not state use of proceeds or the prior close.
• 3d ago AI analysis › Press Release ⚠ 2
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Arcus Biosciences has commenced an underwritten public offering of its common stock, with all shares sold by the company.
Underwriters hold a 30-day option to purchase up to an additional 15% of the shares offered; offering size, price, and terms are not yet set and remain subject to market conditions.
Jefferies, Leerink Partners, and TD Cowen are joint book-running managers. As a late clinical-stage biotech, the raise is dilutive but provides funding runway for its oncology pipeline.
• 4d ago AI analysis › SEC Filing
RCUS: 8-K · earnings release
Arcus Biosciences filed an 8-K estimating approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The figure is a preliminary, unaudited estimate and has not been reviewed by its auditor, Ernst & Young LLP.
The disclosure, furnished under Item 2.02, contains no revenue, earnings, or guidance figures — it is limited to a preliminary liquidity snapshot ahead of full financials. The company notes the estimate may change once financial closing procedures are complete.
SEC 8-K • 4d ago AI analysis › Press Release ● Major ⚠ 3
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Arcus Biosciences presented new ARC-20 data showing casdatifan, its next-generation HIF-2α inhibitor, outperforming third-party benchmarks across first-, second- and late-line clear cell renal cell carcinoma.
In the first line, casdatifan plus zimberelimab delivered 86% and 69% landmark PFS at 6 and 12 months versus 65% and 50% for the ipilimumab/nivolumab standard of care. In the second line, casdatifan plus cabozantinib achieved a 14.5-month median PFS versus ~10 months for cabozantinib alone, and late-line monotherapy produced a 35-month median OS — more than a year beyond the only approved HIF-2α inhibitor.
Two registrational programs anchor the strategy: the ongoing Phase 3 PEAK-1 study (2L, casdatifan plus cabozantinib) and the first-line PEAK-20 study, on track to start by year-end 2026.
Caveat: all comparisons are cross-trial benchmarks, not head-to-head data, and casdatifan remains investigational with no regulatory approval to date.
• 5d ago AI analysis › Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted 2 new employees options to purchase 9,150 shares at $23.83 and RSUs covering 4,600 shares as employment inducement awards.
The grants were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception and priced at the October 8, 2026 closing price.
This is a routine boilerplate equity grant disclosure with no bearing on the company's clinical pipeline or financial outlook.
• 16d ago AI analysis › Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted four new employees options to purchase 21,200 shares at $26.39 per share, plus RSUs covering 10,650 shares.
The awards were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception, meaning they were not shareholder-approved.
This is routine new-hire compensation boilerplate with no bearing on the clinical pipeline, including casdatifan and quemliclustat.
• 1mo ago AI analysis › Press Release ⚠ 3
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Arcus Biosciences will host an in-person investor event with a live webcast on October 20, 2026, at 8:30 AM ET in New York City, featuring new casdatifan data in clear cell renal cell carcinoma across first-, second- and late-line settings.
The data preview covers 30 patients on casdatifan plus zimberelimab in the first line, roughly 20 on a triple combination with ipilimumab, 43 on casdatifan plus cabozantinib in the second line, and 121 pooled monotherapy patients, with ORR, PFS, OS and the first translational data correlating HIF-2a inhibition markers with overall survival.
Arcus reaffirmed that the Phase 3 PEAK-1 trial of casdatifan plus cabozantinib should be fully enrolled by the end of 2026, with initiation of the first-line Phase 3 PEAK-20 study expected in the fourth quarter of 2026.
No actual efficacy results appear in this release; the numbers arrive at the October 20 event, making it a scheduled catalyst for Arcus's lead wholly owned asset, in which Taiho holds rights only in Japan and Asia excluding China.
• 1mo ago AI analysis › News
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com • 1mo ago Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted a new employee stock options to purchase 26,350 shares at an exercise price of $29.06, plus restricted stock units covering 13,200 shares.
The awards were made under the company's 2020 Inducement Plan, approved in January 2020 under the NYSE inducement exception (Rule 303A.08), which permits equity grants to new hires without shareholder approval.
The grants reflect the September 8, 2026 closing price and are routine new-hire compensation with no bearing on the company's clinical pipeline or financial position.
• 1mo ago AI analysis › News
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com • 1mo ago Press Release
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Arcus Biosciences announced that its management team will participate in three investor conferences throughout September 2026.
The scheduled events include the Citi 2026 Biotech Back to School Conference on Sept. 9, the Cantor Fitzgerald Global Healthcare Conference on Sept. 10, and the Morgan Stanley 24th Annual Global Healthcare Conference on Sept. 15.
Live webcasts of the fireside chats will be available on the company's website, with replays accessible following the conclusion of each event.
• 1mo ago AI analysis › Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted employment inducement awards to a new employee, consisting of options to purchase 2,850 shares and restricted stock units for 1,450 shares.
The options have an exercise price of $28.72 per share, matching the closing price on August 10, 2026.
These awards were issued under the Company’s 2020 Inducement Plan in accordance with NYSE Listed Company Manual Rule 303A.08.
• 2mo ago AI analysis › News
Arcus Biosciences Q2 Earnings Call Highlights
marketbeat.com • 2mo ago SEC Filing ⚠ 3
RCUS: SCHEDULE 13D/A · ownership disclosure
Gilead Sciences filed an amended Schedule 13D on Arcus Biosciences attaching an Amended and Restated Investor Rights Agreement dated August 5, 2026, which amends and restates in its entirety the original May 27, 2020 agreement previously amended on October 11, 2022 and January 29, 2024.
The agreement governs Gilead's holdings of Arcus common stock: Gilead may not transfer shares without company consent until the earliest of the third anniversary of the closing date, termination of the parties' collaboration agreement, or termination of the agreement itself, and must observe market stand-off restrictions of up to 90 days around underwritten offerings.
Arcus is obligated to file and maintain Form S-3 resale registration statements for Gilead's shares, bear all registration expenses, and grant Gilead piggyback registration rights for five years after the lock-up expires, while Gilead's disposition volumes after the lock-up are governed by confidential redacted limits.
The filing signals continuity of the Gilead-Arcus collaboration and purchase relationship rather than a new transaction; the exhibits disclose no share counts or ownership percentages, and key commercial terms such as volume caps and ownership thresholds are redacted as confidential.
SEC SCHEDULE 13D/A • 2mo ago AI analysis › News
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago News
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
zacks.com • 2mo ago Press Release ⚠ 3
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus reported Q2 revenue of $41 million, down from $160 million in the prior year, and a net loss of $91 million or $0.72 per share, primarily due to decreased partnership revenues.
The company announced the discontinuation of the domvanalimab program and Phase 3 PACIFIC-8 study, prompting Gilead to relinquish its board seats, while simultaneously advancing lead asset casdatifan through new collaborations with BMS, Summit Therapeutics, and AVEO Oncology.
With $775 million in cash, Arcus maintains a runway into the second half of 2028 and reiterated full-year 2026 revenue guidance of $65 million to $75 million.
• 2mo ago AI analysis › Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted employment inducement awards to three new employees, consisting of options to purchase 12,600 shares and RSUs covering 6,300 shares.
The options have an exercise price of $29.73 per share, which was the closing price on July 23, 2026.
These awards were issued pursuant to the Company’s 2020 Inducement Plan in accordance with NYSE Listed Company Manual Rule 303A.08.
• 2mo ago AI analysis › Press Release
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Arcus Biosciences entered a clinical supply agreement with AVEO Oncology to evaluate casdatifan in combination with tivozanib for advanced kidney cancer patients.
The agreement supports a new randomized cohort within the ARC-20 platform study, testing the combination versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapy.
Enrollment for this cohort is expected to begin in the fourth quarter of 2026, with Arcus retaining full rights to casdatifan.
• 3mo ago AI analysis › Press Release
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Arcus Biosciences announced a clinical trial collaboration with Summit Therapeutics to evaluate its HIF-2α inhibitor casdatifan in combination with Summit's ivonescimab for the treatment of clear cell renal cell carcinoma (ccRCC).
The study will be added as a new cohort to Arcus's ongoing ARC-20 platform study, with costs shared between the two companies and data expected by mid-2027.
This partnership supports Arcus's strategy to establish casdatifan as a backbone therapy across multiple lines of treatment for kidney cancer.
• 3mo ago AI analysis › Press Release
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Arcus Biosciences announced it will host a conference call on August 5, 2026, to discuss its second-quarter 2026 financial results and provide pipeline updates.
The call is scheduled for 4:30 PM ET and will be accessible via live webcast and teleconference, with a replay available shortly after the event.
The company is a clinical-stage biopharmaceutical firm focused on cancer and inflammatory diseases, with key assets including casdatifan and quemliclustat.
• 3mo ago AI analysis › News
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
benzinga.com • 3mo ago News
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
fool.com • 3mo ago Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted employment inducement awards to five new employees, consisting of options for 16,060 shares and RSUs for 8,080 shares.
The options carry an exercise price of $30.26 per share, matching the closing price on July 8, 2026.
These awards were issued under the company’s 2020 Inducement Plan in accordance with NYSE listing rules.
• 3mo ago AI analysis › Press Release ● Major
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Arcus Biosciences announced the publication of research in Nature linking HIF-2a biology with clinical activity for casdatifan in advanced kidney cancer.
The study showed that deep suppression of serum EPO correlated with better outcomes, with a pooled analysis showing a median progression-free survival of 12.2 months in heavily pre-treated patients.
At the Phase 3 dose, median PFS reached 15.1 months in a later analysis with a 35% objective response rate, supporting the ongoing PEAK-1 trial and a planned first-line Phase 3 study.
• 3mo ago AI analysis › Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted employment inducement awards to two new employees, consisting of options to purchase 18,400 shares and restricted stock units for 9,250 shares.
The options carry an exercise price of $28.18 per share, which was the closing price on June 23, 2026.
These awards were issued pursuant to the Company's 2020 Inducement Plan in accordance with NYSE Listed Company Manual Rule 303A.08.
• 4mo ago AI analysis › SEC Filing
RCUS: 8-K · proxy statement
Arcus Biosciences held its annual meeting of stockholders on June 11, 2026. The company reported the voting results in a Form 8-K filing dated June 12, 2026.
Shareholders elected four Class II directors to serve until the 2029 annual meeting. The elected nominees are Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier.
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Additionally, the executive compensation proposal was approved on an advisory basis.
SEC 8-K • 4mo ago News
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com • 4mo ago Press Release
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences granted inducement equity awards to one new employee, consisting of options to purchase 2,850 shares and restricted stock units for 1,450 shares.
The exercise price was set at $23.32 per share, matching the closing price on June 8, 2026, under the company's 2020 Inducement Plan.
• 4mo ago AI analysis › Press Release
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Arcus Biosciences has entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in combination with BMS’s investigational bispecific antibody pumitamig.
Casdatifan will be added as two new arms to the BMS-sponsored Phase 1/2 ROSETTA RCC-208 trial for advanced renal cell carcinoma, allowing Arcus to generate data on its lead asset in a partner-operationalized setting.
The deal supports Arcus’s strategy to establish casdatifan as a backbone therapy in kidney cancer, with each company retaining development and commercial rights to its respective assets.
• 4mo ago AI analysis › Press Release
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Arcus Biosciences management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for June 9, 2026, at 10:40am ET in Miami Beach.
A live webcast and replay will be available on the company's investor relations website.
• 4mo ago AI analysis › News
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
seekingalpha.com • 5mo ago News
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
zacks.com • 5mo ago Press Release ● Major ⚠ 2
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus reported Q1 revenue of $17 million, down from $28 million in the prior year, with a net loss of $128 million.
The company announced the discontinuation of its Phase 3 STAR-121 study evaluating domvanalimab plus zimberelimab in first-line NSCLC due to futility, marking a setback for its TIGIT program.
Offsetting the news, Arcus holds $876 million in cash providing a runway into the second half of 2028 and expects full-year 2026 revenue between $50 million and $65 million.
Pipeline progress includes the selection of inflammation candidate AB102, expected to enter the clinic in Q3 2026, and planned initiation of a Phase 3 study for casdatifan by year-end.
• 5mo ago AI analysis › News
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
zacks.com • 5mo ago Press Release ● Major
Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com • 6mo ago News
What's Going On With Arcus Biosciences Stock On Wednesday?
benzinga.com • 6mo ago News
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
zacks.com • 6mo ago Press Release ● Major
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
businesswire.com • 6mo ago News
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
defenseworld.net • 6mo ago Press Release ● Major
Arcus Biosciences Announces New Employment Inducement Grants
businesswire.com • 6mo ago News
Arcus Biosciences (NYSE:RCUS) Trading Up 5.4% Following Analyst Upgrade
defenseworld.net • 6mo ago Recent SEC filings with analysis 
